Introduction
Hospital-acquired bacterial infections, mainly caused by the nosocomial pathogens such as Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae and so on, pose the foremost challenge to the well-being of a patient. 1 The bacteria counteracts the host's innate immune defense machinery, 2, 3 which becomes the prime cause of death in patients confined to the intensive care unit (ICU), with weakened immune system, culminating in invasive bloodstream infections. The widespread use of broad-spectrum antibiotics [5] [6] [7] Their large surface area relative to volume enables intimate interactions with microbial membranes, as well as surface functionalization, which help in developing more effective antibacterial agents. Over the last decade, there has been a remarkable global focus on conventional as well as biogenic metallic nanoparticles (NPs) as innovative tools for combating the high rates of antimicrobial resistance. Chemotherapeutic drugs when given in combination with metallic NPs may result in a cumulative effect due to the antibiotic as well as the metal ions released from NPs. Moreover, the antibacterial agent may be used at a much lower dose than when administered alone, hence overcoming the problem of resistance and diminishing other undesirable side effects to some extent. 6, 8 There has also been a paradigm shift in management of biofilms and MDR bacteria with polymeric nanocomposites and antibiotic-loaded polymeric NPs. Improved therapeutic efficacy with concomitant decline in side effects of antimicrobial drugs has also been achieved by surface modification of metallic NPs with ligands or antibodies for targeted delivery.
This review summarizes the immune evasion strategies and antibiotic resistance mechanisms employed by bacteria to survive in the host and the probable metallic nanomaterialsbased bactericidal effects to fight against nosocomial pathogens. The antibacterial activities of biologically synthesized metallic NPs as well as polymeric nanocomposites and surface-modified NPs are also highlighted. The metal-based nanomaterials alone or functionalized with antibiotics when translated to clinics may show promise as next-generation nanotherapeutics against bacterial menace.
Gravity of the problem
Bacterial infections have emerged as the leading cause of the formidable rates of deaths in hospitalized and immunosuppressed patients, especially those in ICUs and those undergoing invasive operations, worldwide 1, 4, [9] [10] [11] as well as in parts of Saudi Arabia where the prevalence has been reported to be 31.7%. 12 The hospital-acquired infections manifest in a wide gamut of severe clinical ramifications, such as bacteremia, septic shock, ventilator-related pneumonia and massive soft tissue necrosis, and rapidly progress to systemic infections that eventually culminate in multiorgan failure and death. 13 The control measures including implementation of hygiene, patient isolation and environmental decontamination have proved ineffective in keeping the infection at bay. Improper use of antibiotics has favored an upward trend in the development of resistance to almost all the available drugs, further compounding the clinical problem. 9, 14 The challenge to control these infections is augmented in MDR bacteria such as those producing extended-spectrum β-lactamases and carbapenemases (K. pneumoniae carbapenase) and in methicillin-resistant S. aureus (MRSA). Drug combination regimens have also proved ineffective due to formation of biofilms, agglomerates of bacterial colonies that adhere to a surface and resist traditional means of killing by avoiding contact with the antibiotics. 15 The bacteria survive in the biofilms for extended periods of time and are likely to be transmitted within the health care settings. The quandary of mechanisms of antibiotic resistance has retrogressed the clinical outcome and inflated the economic burden of infectious diseases, leaving the medical practitioners with few therapeutic options to address the emerging threat. 14 Furthermore, an arsenal of strategies has been employed by bacteria to subvert the host immune system, adversely impacting the surrogate markers of clinical course such as the length of hospitalization and hospital-related deaths.
Bacteria's stratagem: targeting the innate immune defense
The bacteria have evolved a diverse array of resistance mechanisms to disable key players of the host innate immune defenses for their survival ( Figure 1A ). They utilize a multitude of virulence factors that conjointly render substantial impediment to phagocytes (macrophages and neutrophils) recruitment and activation. 3 The bacteria parasitize host cells by arresting or reprogramming phagosomal maturation, by escaping maturing phagosomes or by withstanding the microbicidal properties of the phagolysosome. They acquire resistant proteins to withstand low pH environment of phagosomes. The bacteria escape neutrophils extracellular traps (NETs) and elude opsonophagocytosis, and the cytocidal effects of host's antimicrobial peptides (AMPs) and reactive oxygen species (ROS). They secrete proteases that cleave NETs, degrade AMPs and express detoxifying enzymes like catalase to neutralize ROS and convert them into less harmful compounds. 16 Bacteria may also impair ROS production. Bacteria trigger phagocytic death through pore-forming cytolysins and escape host complement deposition and activation. 2 They release complementdegrading and complement-inactivating enzymes and inhibit membrane attack complex polymerization, thereby impeding bacteriolysis. Self-colonization of bacteria to form biofilms further leads to immune subterfuge. 6 Bacteria subvert 
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Nanomaterials as antibacterial agents the T cell stimulation by dendritic cells (DCs), through downregulation of their antigen-presenting or costimulatory functions. Bacteria may directly infect DC, dampening its interleukin (IL)-12 and tumor necrosis factor-alpha (TNF-α) production, thereby crippling the adaptive immune response. 17 Immune evasion favors bacterial persistence, resulting in increased antibiotic use and selection for MDR pathogens, thus emphasizing the need for alternate antimicrobial therapies. 16 
The emergence of antibiotic resistance
In the present era, the quintessential antibiotics remain the mainstay for management of invasive infections, to annihilate or restrain the growth of a vast spectrum of bacteria. However, this perspective advocates ever-expanding threats accountable to indiscriminate use of antimicrobials resulting in escalated incidence of antibiotic resistance and epidemics of hypervirulent pathogens among vulnerable patients. 14 Bacteria have progressively eroded the effectiveness of not only a single antibiotic by developing resistance but concurrently multiple drugs that were previously effective. Intracellular bacteria are difficult to treat with regular antimicrobial therapies, resulting in chronic infections. Medical devices such as catheters, implants and sutures increase the risks of nosocomial infections due to formation of biofilms. The biofilm-related infections are extremely defiant to antimicrobial arsenal and spread rampantly in the community. 15 The normal gut microbiota that otherwise maintains the immune functions is also targeted by antibiotic spectrum. Drug-resistant bacterial infections entail higher doses of drugs, with augmented toxicity, longer hospital stays and enhanced mortality. Thus, antimicrobial resistance remains a substantial global health concern, invigorating the critical need for alternate therapeutic options to combat chronic intracellular infections and biofilms so as to shorten the hospital stays, and hence mortality.
Drug resistance subterfuge evolved by bacteria
The acquisition of resistance to single and multiple antibiotics by bacteria ( Figure 1B ) has been reported to occur through horizontal gene transfer on plasmids or transposons by transformation, conjugation and transduction or by spontaneously mutating the existing genes. 18 The resistance becomes rampant due to selective pressure for microbes expressing resistance genes against the antimicrobial drug, created by overuse of antibiotics, non-patient compliance or use of timedependent drugs with long half-lives or microbiostatic drugs. 7 Modes of resistance mechanisms 19 that endanger the efficacy of antibiotic arsenal are summed up as follows.
Active antimicrobial drug efflux and reduced uptake Drug efflux pumps preclude the entry of drugs or extrude the antibacterial agent from the microbial cell before it 
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Hemeg reaches its target site to exert its effect. Overexpression of transmembrane multidrug efflux pumps as well as reduced uptake results in sub-toxic levels of drugs within the microbial cells. 20 In P. aeruginosa, mutation in regulatory protein that normally dampens the gene encoding efflux proteins results in enhanced outpour. E. coli uses transmembrane proton gradient to expel multiple antibiotics through its numerous efflux pumps. The increased drug resistance of Gram-positive bacteria is also attributed to the outer membrane surrounding the periplasmic space that restrains the uptake of hydrophobic drugs. The antibiotic uptake or efflux may also be affected by mutations such as the diminished expression or absence of porins in P. aeruginosa, lowering the permeability of the cell wall to carbapenems. 21 In case of both Gram-positive and Gram-negative bacteria, one of the genes encoding tetracycline efflux pumps (TetA) is normally not expressed due to TetR repressor protein. However, tetracycline binds to and inactivates TetR, thereby inducing TetA expression that catalyzes drug efflux. 7 expression of resistance gene encoding altered substrate
The antibacterial agent has diminished affinity for the resistance gene-encoded altered antibiotic target sites on the substrate than the wild-type site. This is exemplified in case of penicillin-resistant Streptococcus pneumoniae (due to MecA gene conferring resistance to all β-lactams), vancomycin-resistant S. aureus and vancomycin-resistant Enterococcus (due to VanA resistance gene), sulfonamideresistant S. pneumoniae, Streptococcus pyogenes, Neisseria spp. and E. coli. 7 This mechanism also accounts for conferring resistance against aminoglycosides, macrolides, β-lactams, sulfonamides, linezolid, tetracyclines, rifampin and quinolones. 7, 22 Resistance genes coding for enzymes that methylate 23S rRNA of the 50S ribosomal subunit and 16S rRNA of the 30S ribosomal subunit inhibit binding by macrolides (such as erythromycin) and aminoglycosides, respectively.
7,23
Covalent modification of antimicrobial drug, dampening its efficacy Plasmids or transposons and rarely bacterial chromosomes harbor resistance genes encoding aminoglycoside-modifying enzymes that covalently alter the OH or NH 2 groups on aminoglycosides, thereby undermining their affinity for 30S ribosomal subunit, and waning their antimicrobial activity. β-Lactamases, having broad-spectrum activity against most of the β-lactam antibiotics, including cephalosporins, have evolved by gene transfer. 5, 21 Chloramphenicol acetyltransferases modify chloramphenicol, making it unable to bind to 50S ribosomal subunit and inhibit protein synthesis. Covalent modification also affords resistance against tobramycin, gentamycin, chloramphenicol, kanamycin, macrolides, tetracyclines, quinolones and streptogramins. 7, 23 Synthesis of a competitive inhibitor of antibiotic S. aureus and Neisseria meningitidis acquire sulfonamide resistance by producing its inhibitor (para-aminobenzoic acid) that competes for binding the active site of bacterial dihydropteroate synthetase. 7, 24 Mutations in this enzyme have also been found in many clinical isolates, downgrading sulfonamide-based therapies to second-or thirdline options.
Biofilm formation to avoid contact with antibiotics
Biofilms are surface-adherent aggregates of bacterial communities embedded within an extracellular, self-produced, polymeric matrix. Intracellular bacteria in biofilms have limited exposure to antibiotics. Biofilms also act as a barrier of diffusion by trapping and degrading antibiotics and thus render tolerance to even high concentrations of antibiotics, a phenomenon called recalcitrance, resulting in recurrent or chronic bacterial infections as with S. aureus and P. aeruginosa. 15 Biofilms can also favor gene transfer between bacteria, thus spreading antibiotic resistance and transforming a previously non-virulent commensal into a virulent pathogen. 25 
Nanotechnology-based therapeutic interventions to fight nosocomial pathogens
Several metals, metal oxides, metal halides and bimetals in nanoparticulate form have been documented for antimicrobial activity 5, 26 as the bacteria are less likely to develop resistance to nanomaterials. These comprise NPs containing Ag, Au, Zn, Cu, Ti, Mg, Ni, Ce, Se, Al, Cd, Y, Pd and superparamagnetic Fe. Zerovalent bismuth-containing NPs have shown promise in treating infections due to drug-resistant bacteria in combination with X-rays. 27 Among the metalcontaining NPs, Au NPs have moderate antibacterial activity unless their surface is modified. Ag NPs are the most effective nano-weapon against bacterial infections. [28] [29] [30] On the other hand, upsurge in resistance to Ag NPs has been reported due to genetic alterations in bacteria. 31 The deposition of silver 32 The high toxicity of CuO NPs causes oxidative lesions, while DNA damage induced by ZnO and TiO 2 NPs limits the efficacy of these NPs. Nonetheless, NPs have emerged as alternative antimicrobial approach to combat biofilms and for treating severe bacterial infections. 33 The NPs-mediated elimination of the microbes may be microbicidal, or the effect may be microbiostatic, wherein the growth of bacteria is arrested and metabolic activities are ceased and the killing is potentiated by the host's immune cells.
Mode of action of metal-based nanomaterials
Metallic NPs use multifaceted contrivance simultaneously to combat microbes (Figure 2 ), depreciating the probability of development of resistance, as it would entail multiple concurrent gene mutations in the same microbe for evolvement of that resistance. The molecular mechanisms by which metalbased NPs annihilate MDR bacteria, resulting in disturbance in respiration and inhibition of cellular growth, have been extensively reviewed. 28, 29, 33 
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Hemeg dysfunctional. Ag + also precludes cell wall synthesis in Gram-positive bacteria. Cu ++ interacts with amine and carboxyl groups on the surfaces of microbial cells, such as Bacillus subtilis. 40 Au NPs also result in bacterial membrane disruption.
Intercalation between DNA bases
Ag + released from NPs has also been reported to interact with DNA of microbes, 28, 29 and inhibit DNA replication and cell division. Inhibition of DNA replication and DNA degradation has also been reported with Cu NPs. 37, 40 Bi NPs in combination with X-ray treatment emit electrons, with formation of free radicals that damage bacterial DNA. 48 
Adsorption of nanomaterials to bacterial cell
The electrostatic interaction between the NPs and the microbial cells affects its toxicity, with the positively charged NPs being more toxic as has been observed with TiO 2 and surfacemodified Au NPs. 36, 41 The NPs adsorption to the surface of 
Alteration in bacterial membrane permeability
Cell surface adherence of Ag and polyvinyl alcohol (PVA)-coated ZnO NPs coupled with ROS generation increases membrane permeability and triggers cell death. 28, 29, 35 The membrane viscosity is also altered, influencing the transport across the membrane. Ag + released from Ag NPs interacts with negatively charged lipopolysaccharide in the bacterial membrane, permeabilizing it and dissipating the electrochemical proton gradient across the membrane, resulting in lysis. 7 
Ag
+ inhibits cytochromes of the electron transport chain, and disrupt cellular transport systems by causing homeostatic imbalance due to K + loss from the membrane. Loss of membrane potential and disruption of respiratory chain has also been observed with Au, 43 Cu 37 and NiO NPs. 44 
Penetration of the cell envelope and ribosome destabilization
The NP surface charge also affects the internalization and subcellular localization and hence toxicity as with CeCl 2 NPs. 45 Entering of NPs into the cytoplasm to exert microbicidal effects via oxidative stress has been observed with Ag nanomaterials 28, 29 and PVA-coated ZnO NPs. 35 MgF 2 NPs cause lipid peroxidation and enter the membrane of microbial cells, causing a fall in cytoplasmic pH, which raises the membrane potential. 38 Al 2 O 3 NPs cause oxidative damage to membrane and enter cytoplasm. 32 Ag and Au NPs have been reported to exert toxicity by penetrating inside the cell and denaturing 30S ribosomal subunit, thereby impeding protein translation.
29,30,41

Disruption of bacterial biofilms
During bacterial biofilm maturation, the extracellular matrix (slime) and extracellular carbohydrates known as quorum sensing molecules (for cell-to-cell communication) are produced. 46 The slow-growing bacterial cells detach, resulting in spread of infection. Ag 28, 29 
Antibacterial activities of ecofriendly green NPs
The potentiality of prokaryotes and plants to reduce inorganic metals has advanced a stimulating, cost-effective strategy towards the NPs synthesis via green nanotechnology. 57 Plant-as well as microbe-mediated metallic NPs synthesis (bottom-up or biological method) avoids the generation of toxic by-products, and is hence ecofriendly and a green alternative to conventional methods (top-down or physical methods and bottom-up or chemical methods) for mining nanomaterials. 58 The biologically synthesized metallic NPs are biocompatible and potentially safe for human therapeutic use. A plethora of literature highlights the antimicrobial activities of biogenic metallic NPs ( 60 Ag NPs synthesized using leaves extract of Skimmia laureola, 61 root extract of Delphinium denudatum, 62 Styrax benzoin extract 63 and Rosa chinensis flower extract 64 showed potent antibacterial effects against a spectrum of Gram-positive and Gramnegative human pathogenic bacteria. Ag NPs synthesized using Caesalpinia sappan extract served as a potential novel nanoantibiotic against MRSA. 65 Biologically synthesized Ag NPs using Coffea arabica seed extract have been found to exhibit significant antibacterial activity against E. coli and S. aureus, that was almost equivalent to that elicited with the standard drug ampicillin. 66 Inhibitory activity of green synthesized ZnO NPs from Solanum nigrum, 67 CeO 2 NPs from Olea europaea leaf extract, 68 and Fe 3 O 4 -Ag core shell magnetic NPs obtained using Vitis vinifera stem extract 69 against both Gram-positive and Gram-negative pathogens has also been reported. The antibacterial activities of biologically synthesized NPs are due to the metal ions released from the NPs, coupled with the bio-organic compounds used in the green synthesis that may interact with the microbial membrane as well as preclude the need for reducing and stabilizing agent. 70 However, the biosynthetic NPs have not been found to surpass the non-biosynthetic NPs in antibacterial effects or vice versa.
Immunomodulatory effects of nanomaterials based on metals
Metal-based NPs are known to trigger innate as well as adaptive immune responses. 86 The immunostimulatory 
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Hemeg potential of Ag, CeO 2 and surface-modified Au NPs has been reported. 87 Immunostimulatory NPs may serve as doubleedged swords by acting on bacteria as biocidal nanoweapons, as well as undermining the bacterial resistance to host immunity. ZnO NPs increased interferon gamma, TNF-α and IL-12 expression in primary human immune cells, 88 while in another study, IL-6, IL-1β, IL-8 and TNF-α were induced by ZnO NPs from peripheral blood mononuclear cells. 53 TiO 2 89 and SiO 2 NPs 90 activated inflammasomes and induced IL-1β release, which affected fibroblast proliferation. Ag NPs also induced inflammasome formation and triggered IL-1β release and subsequent caspase-1 activation. 91 Size-dependent immunomodulatory effect of Au NPs has been reported that may inhibit IL-12p70 production by DCs and Th2 polarization, or promote Th17 potentiation. 92 CeO 2 NPs stimulated IL-10 production from DCs and triggered a strong Th2-biased cytokine profile. On the contrary, TiO 2 NPs induced DCs to release IL-12 and polarize T cells to a Th1-bias. 93 TiO 2 NPs and nanoplatinum triggered proinflammatory cytokine production, DC maturation and näive T cell activation and proliferation. 94, 95 A benign ε-polylysine/Ag nanocomposite has been reported to modulate the relative levels of CD3 +
T cells and CD68
+ macrophages and promote infected wound healing. 96 
Synergistic antibacterial effects of nanomaterials with antibiotics or alternate antimicrobial compounds
While most metal-based NPs are microbicidal to an array of bacteria, genetic alterations in bacteria may result in rapid evolution of resistance to Ag NPs, 31 whereas Al 2 O 3 NPs trigger increased expression of conjugation-promoting genes, thus promoting horizontal transfer of antibiotic resistance genes. NPs have been tailored to subdue resistance 
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Nanomaterials as antibacterial agents by packaging multifarious antimicrobial agents, resulting in development of resistance, which is a subtle possibility since it would require multiple simultaneous gene mutations in the same bacteria. 97, 98 The functionalization of NPs using antibiotics (Table 3) is not only a promising nanoplatform to combat bacterial resistance but may also reduce the dose and hence toxicity of the drugs. NPs target or deliver antimicrobial agents to the infected site, thereby overcoming resistance as well as mitigating their hazardous impact on normal cells. Synergistic antibacterial efficiency of Ag NPs and antibiotics has been observed against S. aureus, E. coli and P. aeruginosa at extremely low concentrations. 99 The efficacy of ampicillin coupled with Ag NPs was identical in Gram-positive and Gram-negative bacteria, unlike the difficulty in inhibition of Gram-positive bacteria with Ag NPs alone. 39 Green synthesized NPs may also be used as an antibiotic adjuvant for the treatment of various bacterial infections (Table 3) . Ag NPs boost the antimicrobial effects of several antibiotics, including penicillin G, amoxicillin, vancomycin, clindamycin and erythromycin against S. aureus, E. coli and MDR bacteria. 100 The antibiotic-functionalized NPs may promote reversal of antimicrobial resistance.
Combinatorial effect of Ag NPs with natural alternative compounds such as cinnamaldehyde 117 and eugenol 118 has also been reported. Se NPs conjugated with quercetin and 
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Hemeg acetylcholine had synergistic effect against MRSA, causing irreversible membrane damage. 119 Resveratrol nanocarriers with Au NPs and Ag NPs had potent activity against Grampositive and Gram-negative bacteria. 120 The combination of biologically synthesized Ag NPs (produced by Fusarium oxysporum) and oregano (Origanum vulgare) essential oil showed bactericidal effects against non-methicillin-resistant S. aureus (non-MRSA) and β-lactamase-and carbapenemaseproducing E. coli and A. baumannii strains. 121 Nigella sativa essential oil-synthesized Au NPs effectively inhibited the biofilm formation of S. aureus and Vibrio harveyi.
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Polymeric nanocomposites and nanomaterials conjugated with antibodies and other ligands and drug-NP complex for targeted delivery
Antimicrobial NPs can be easily trapped within polymer films to form lipid-polymer hybrid NPs or nanocomposites. Enhanced biocompatibility and stability coupled with controlled release make these superior alternatives to metallic NPs. Synergistic antibacterial effects of some polymers and metal nanomaterials have been identified. The biocidal activities of Ag and Cu NPs embedded in polymer matrices have been reported to be enhanced due to release of metal ions while dampening their toxicities. 55, 123 Ag nanocomposites have been reported to be biocidal against MRSA. 124 A benign ε-polylysine/Ag nanocomposite demonstrated antibacterial effects against P. aeruginosa and S. aureus that was mediated by surface adherence, irreversible disruption of the membrane with subsequent penetration and inhibition of protein activity, ultimately leading to bacterial apoptosis. 96 Low-density polyethylene-containing ZnO nanocomposites have been found to be effective against B. subtilis and Enterobacter aerogenes. 125 127 Targeted NP delivery to the infection site could also be achieved by surface modification with ligands or antibodies, which may further improve therapeutic efficacy and reduce the side effects of antimicrobial drugs. The effectiveness of Ag NPs is also augmented with compounds such as polyethyleneimines, chitosan and glucosamine that serve as ligands and reinforce their uptake into bacterial cells. 128 Chitosan has inherent antimicrobial properties due its polycationic character. Low-molecular weight chitosan-coated Ag NPs have been reported to surpass polyvinylpyrrolidone-coated Ag NPs and Ag NPs without surface stabilizer (uncoated Ag NPs) in efficacy against MRSA with enhanced biocompatibility and reduced body absorption characteristics. 129 Chitosan/TiO 2 / Ag nanocomposites exhibited effective antibacterial activity via ROS generation, lactate dehydrogenase release and inhibited bacterial adhesion. 130 Chitosan/Ag nanocomposites were effective against Salmonella sp., 131 whereas the activity of chitosan-TiO 2 :Cu nanocomposite against E. coli and S. aureus was enhanced in the presence of light. 132 Chitosan/ calcium silicate nanocomposites doped with Ag + exhibited antibacterial activity against S. aureus and P. aeruginosa. 133 Ag NPs capped with lipoic acid were effective against Staphylococcus epidermidis and Streptococcus mutans biofilm. 134 Ag-decorated poly (DL-lactide-co-glycolide) NPs exhibited high efficacy against S. epidermidis biofilms. 135 Biodegradable lignin-core NPs coated with cationic polyelectrolytes and infused with Ag + exhibited broad-spectrum biocidal activity against Gram-positive as well as Gramnegative bacteria at lower concentrations of Ag + than the conventional Ag NPs and hence suggested as greener alternatives to Ag NPs. 136 Antibacterial (P. aeruginosa) activity of iron oxide NPs was also enhanced upon chitosan coating. 137 Superior antibacterial activity of UV-irradiated glucosamine-functionalized Au NPs on graphene oxide against E. coli and Enterococcus faecalis has been reported that was better than kanamycin. 138 Gallic acid-capped Au NPs have been found to be effective against both Gram-positive and Gram-negative bacteria. 139 Synthetic peptides (containing arginine, tryptophan and cysteine termini)-immobilized Au NPs exhibited targeting capacity and activity against Staphylococci, Enterococci and antibiotic-resistant bacterial strains. 140 Microbial (Ochrobactrum rhizosphaerae) glycolipoprotein-capped Ag NPs exhibited antibacterial activity against V. cholerae comparable to ciprofloxacin. 141 Besides the targeting ligands, NPs conjugated with antibodies against surface antigen of the target microbe such as anti-protein A antibodies have been shown to have high selectivity for killing S. aureus. Conjugating Bi NPs to antibodies against the target has been found to be effective against MDR P. aeruginosa when irradiated with low-dose X-rays. 54 Similarly, the IgG in IgG-Fe 3 O 4 @TiO 2 magnetic NPs has been shown to target S. pyogenes. 
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Nanomaterials as antibacterial agents in the presence of anti-toxin antibody secreted by S. aureus, inhibiting its growth. 142 Lipids like phosphatidylinositol and stearylamine presented specific affinity with biofilms, thereby increasing the biofilm adhesion of liposomes. Anti-biofilm activities of phosphatidylcholine-decorated Au NPs loaded with gentamycin have been reported against P. aeruginosa, S. aureus as well as intracellular Listeria monocytogenes and E. coli. 143 NP-based drug delivery could subjugate systemic toxic effects of antibiotics, decrease uptake and increase efflux of drugs, biofilm formation and intracellular bacterial infection.
Conclusion and perspectives
Bacteria are increasingly dodging extermination as they have evolved innate immune resistance strategies. Antibiotics remain the mainstay to fight bacterial infections, but episodes of resistant infections are alarmingly on the rise. The indiscriminate use of antimicrobial agents in the community, hospital and agriculture is undeniably responsible for fuelling this crisis. This also causes selective pressure, allowing only the fittest genotype to thrive, resulting in emergence of MDR bacterial strains, and emphasizing the need for surrogate therapeutic options. The emergence of resistant and more virulent strains of bacteria has outpaced the development of new antibiotics over the last few decades. NPs are now being considered as a viable alternative to antibiotics due to their biocidal and immunopotentiating properties. The polymerbased nanomaterials and metal NPs may also be exploited as antimicrobial coatings on surface of medical devices for various biomedical applications. Metallic NPs when used with the existing antibiotics for bacterial infections lower the antibiotics dosage to be administered, thereby minimizing toxicity as well as reducing the probability of development of resistance. There has been a paradigm shift towards cost-effective and ecofriendly green synthesis of antibacterial NPs. This approach holds promise alone or synergistically with antibiotics targeting various bacterial infections, paving way for future therapeutics in nanomedicine. This combinatorial approach may serve as adjunct to the existing therapies and may help to restrain the escalating nosocomial threats. However, their translation to clinics would entail an in-depth understanding of the pharmacokinetics and biodistribution of NPs.
Disclosure
The author reports no conflicts of interest in this work.
